New scan could end guesswork for brain cancer survivors
NCT ID NCT04462419
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether a PET scan using a radioactive tracer called 18F-Fluciclovine can tell the difference between a returning brain tumor and damage from past radiation therapy. Nineteen people with brain metastases who had suspicious MRI findings took part. The goal was to find the best scan settings to avoid unnecessary treatments for harmless radiation scars.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Fluciclovine F-18 (a radioactive tracer used in PET scans)
- What this could lead to
- If successful, this could give doctors a better way to tell whether a brain lesion after radiation is a returning tumor or harmless scar tissue, avoiding unnecessary surgeries or treatments.
- What could go wrong
- This was a very small, early-phase trial that was terminated early, so results are limited. The technique may not be accurate enough for routine use, and the tracer is not widely available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
19 people
The number who actually took part.
- Started
-
Aug 2020
- Finished
-
Nov 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with intracranial metastatic disease (brain tumor) that has been treated with radiation therapy.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Clinical evidence of intracranial metastatic disease which underwent radiation and who presents with MRI findings suspicious for recurrent disease and/or radionecrosis (namely the 'index lesion') Exclusion Criteria: * Contraindication to contrast enhanced MRI * Females of child-bearing potential who are pregnant or lactating or who are not using adequate contraception (surgical, hormonal or double barrier, i.e. condom and diaphragm) * Inability to lie still for 50 minutes during fluciclovine PET-MRI imaging * Inability or refusal to consent * Allergy or anaphylaxis to any of the reagents used in this study * Inability or unwillingness to return for required visits and follow-up exams
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic intracranial malignant neoplasm are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States